SOURCE: AlphaRx Inc.

September 25, 2006 08:00 ET

AlphaRx Appoints Leading Ophthalmologist to Its Scientific Advisory Board

Top US Clinician Joins the Company's Scientific Advisory Board to Develop Innovative Ophthalmic Products Using Nanotechnology

MARKHAM, ON -- (MARKET WIRE) -- September 25, 2006 -- AlphaRx Inc. (OTCBB: ALRX) is pleased to announce the appointment of Michael S. Berlin, M.D., M.S., dedicated to advancing and improving the care of patients with eye diseases, to its Scientific Advisory Board.

Dr. Berlin is currently a Clinical Professor at the UCLA Jules Stein Eye Institute. He is a member of the American Academy of Ophthalmology, the American Glaucoma Society, and the American Society for Laser Medicine and Surgery. He has researched and published numerous books and articles on glaucoma and laser surgery, and is regularly invited to lecture at professional conferences, both in the United States and internationally.

Dr. Berlin is also the founder and director of the Glaucoma Institute-Beverly Hills, and is a board-certified ophthalmologist specializing in laser surgery and in the research and treatment of glaucoma.

This press release is available on the Company's official online Investor Relations HUB at for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.

About AlphaRx Inc.

AlphaRx is an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including arthritis, tuberculosis, ocular infection and inflammation, cataracts, hospital acquired pneumonia and sepsis.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

Contact Information